Bruce D. Hammock

Dec 11, 2023 | mdpi.com | Jun Yang |Darko Stefanovski |Bruce D. Hammock |Jang H. Youn

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Sep 3, 2023 | nature.com | Wei Shi |Bruce D. Hammock

Dear Editor,A novel bispecific T-cell engager (BiTE) has been developed as an efficient immunotherapeutic molecule specifically bringing the T-cell and the tumor target together for enhanced immunotherapy. The general BiTE construct consists of two single-chain variable antibody fragments (scFvs) targeting a tumor-associated antigen (TAA) and a T-cell marker in tandem.